CLINICAL TRIALS PROFILE FOR SUPRANE

All Clinical Trials for Suprane

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00762372 ↗	Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)	Completed	Baxter Healthcare Corporation	Phase 2/Phase 3	2008-02-01	The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in term of awakening/recovery from anesthesia.
NCT00815269 ↗	Vasodilation Effect of Inhalational Anesthetics	Completed	Nanjing Medical University	N/A	2008-12-01	Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.
NCT01125982 ↗	Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens	Completed	Sykehuset Telemark	Phase 4	2010-06-01	The purpose of this study is to establish validated outcome measures for Postoperative Fatigue and Postoperative nausea, and to compare clinical impact of postanaesthetic symptoms during first week after Propofol or Desflurane based anaesthesia.

Clinical Trial Conditions for Suprane

Condition Name

Condition Name for Suprane
Intervention	Trials
Anesthesia	5
Obesity	2
Idiopathic Scoliosis	2

Condition MeSH

Condition MeSH for Suprane
Intervention	Trials
Scoliosis	2
Respiratory Aspiration	2
Heart Arrest	1

Clinical Trial Locations for Suprane

Trials by Country

Trials by Country for Suprane
Location	Trials
United States	5
Korea, Republic of	4
Egypt	3
Japan	3
Germany	2

Trials by US State

Trials by US State for Suprane
Location	Trials
Ohio	3
New York	1
California	1

Clinical Trial Progress for Suprane

Clinical Trial Phase

Clinical Trial Phase for Suprane
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Suprane
Clinical Trial Phase	Trials
Completed	28
Unknown status	3
Withdrawn	2

Clinical Trial Sponsors for Suprane

Sponsor Name

Sponsor Name for Suprane
Sponsor	Trials
Baxter Healthcare Corporation	4
Theodor Bilharz Research Institute	2
Kangbuk Samsung Hospital	2

Sponsor Type

Sponsor Type for Suprane
Sponsor	Trials
Other	42
Industry	5
U.S. Fed	1

SUPRANE: Clinical Trials, Market Analysis, and Projections

Introduction to SUPRANE

SUPRANE, also known as desflurane, is a potent inhalational anesthetic used in various surgical procedures. It is characterized by its rapid onset and recovery, making it a preferred choice in many clinical settings.

Clinical Trials and Usage

Clinical Studies and Indications

SUPRANE has been extensively studied in clinical trials to assess its safety and efficacy. It is indicated for the maintenance of anesthesia in adults and children after induction with other agents and tracheal intubation. Clinical trials have shown that SUPRANE can be used effectively in pediatric patients aged 2 weeks to 12 years, although it is contraindicated for induction in pediatric patients due to the risk of upper airway irritation and other adverse reactions[4].

Adverse Reactions and Contraindications

Clinical trials have highlighted several adverse reactions associated with SUPRANE, including upper airway irritation, oxyhemoglobin desaturation, and the potential to trigger malignant hyperthermia in susceptible individuals. It is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, those with a history of moderate to severe hepatic dysfunction following anesthesia with halogenated agents, and those with known sensitivity to SUPRANE or other halogenated agents[4].

Market Analysis

Global Inhalation Anesthesia Market

The global inhalation anesthesia market, which includes SUPRANE, is projected to experience significant growth over the coming years. In 2024, the market size was estimated at USD 1.51 billion and is expected to grow at a CAGR of 6.65% from 2025 to 2030, reaching USD 2.22 billion by 2030[5].

Market Segments and Growth Drivers

The market is segmented by drug type, application, and end-use. The sevoflurane segment currently dominates the market, but desflurane (SUPRANE) is also a significant player due to its favorable pharmacokinetic properties. The growth in the inhalation anesthesia market is driven by the increasing number of surgical procedures, particularly in outpatient and same-day discharge contexts, where rapid recovery times are crucial[5].

Regional Market

The North American region is one of the largest markets for inhalation anesthetics, including SUPRANE. Other significant regions include Europe, Asia Pacific, Latin America, and the Middle East & Africa. The U.S. and Canada are key countries within the North American market, while Germany, France, and the UK are significant in Europe[5].

Market Projections

Revenue Growth

The inhalation anesthesia market, which includes SUPRANE, is expected to grow substantially. By 2034, the U.S. inhalation anesthesia market alone is predicted to be worth around USD 1.04 billion, up from USD 620 million in 2024, at a CAGR of 5.97%[2].

Competitive Landscape

Key players in the inhalation anesthesia market include Baxter, AbbVie Inc., Halocarbon Product Corporation, Sandoz International GmbH, and Piramal Enterprises Ltd. These companies are driving innovation and competition in the market, which is expected to further boost the adoption of inhalational anesthetics like SUPRANE[5].

Key Factors Influencing Market Growth

Increasing Surgical Procedures

The global rise in surgical procedures, especially in outpatient settings, is a significant driver for the demand of inhalational anesthetics. SUPRANE's rapid onset and recovery make it an ideal choice for these procedures[5].

Advancements in Anesthetic Techniques

Advancements in anesthetic techniques and the rising demand for safer, more efficient anesthetics are also contributing to the growth of the market. SUPRANE's ability to maintain stable hemodynamics and its minimal airway irritation are key factors in its popularity[5].

Patient Safety and Recovery

The emphasis on patient safety and faster recovery times is another critical factor. SUPRANE's favorable pharmacokinetic properties, such as its pleasant odor and quick recovery profile, make it a preferred choice in many clinical environments[5].

Conclusion

SUPRANE is a vital component of the inhalation anesthesia market, known for its rapid onset and recovery, making it suitable for a wide range of surgical procedures. The market for inhalational anesthetics is expected to grow significantly, driven by increasing surgical procedures, advancements in anesthetic techniques, and a focus on patient safety and recovery.

Key Takeaways

• Clinical Trials: SUPRANE has been studied extensively for its safety and efficacy, particularly in pediatric and adult patients.
• Market Growth: The global inhalation anesthesia market is projected to grow at a CAGR of 6.65% from 2025 to 2030.
• Segment Dominance: Sevoflurane currently dominates the market, but desflurane (SUPRANE) remains a significant player.
• Regional Importance: North America and Europe are key regions for the inhalation anesthesia market.
• Growth Drivers: Increasing surgical procedures, advancements in anesthetic techniques, and a focus on patient safety and recovery are driving market growth.

FAQs

What is SUPRANE used for?

SUPRANE (desflurane) is used for the maintenance of anesthesia in adults and children after induction with other agents and tracheal intubation.

What are the contraindications for SUPRANE?

SUPRANE is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, those with a history of moderate to severe hepatic dysfunction following anesthesia with halogenated agents, and those with known sensitivity to SUPRANE or other halogenated agents.

How does the market for inhalational anesthetics like SUPRANE project to grow?

The global inhalation anesthesia market is expected to grow at a CAGR of 6.65% from 2025 to 2030, reaching USD 2.22 billion by 2030.

What are the key drivers of the growth in the inhalation anesthesia market?

The growth is driven by the increasing number of surgical procedures, advancements in anesthetic techniques, and a focus on patient safety and faster recovery times.

Which regions are significant for the inhalation anesthesia market?

North America and Europe are key regions, with the U.S. and Canada being significant in North America, and Germany, France, and the UK in Europe.

Sources

1. Clinical Trial Update October 2024 - Retinal Physician
2. Inhalation Anesthesia Market Size To Hit USD 3.61 Bn By 2034 - Precedence Research
3. Anesthesia Drugs Market Size & Share | Global Trends 2032 - SNS Insider
4. SUPRANE - accessdata.fda.gov
5. Inhalation Anesthesia Market Size And Share Report, 2030 - Grand View Research